A new, shorter and safer drug regime for latent tuberculosis could help curb the global epidemic by increasing the numbers successfully treated and reducing the pool of infection, researchers believe.
Two groundbreaking studies, one in adults and the other in children, have trialled a less toxic drug than the one in current use worldwide for latent TB and cut the treatment time from nine months to four.
